Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial

DOI: 10.1093/eurheartj/ehi443
European Heart Journal, 2006, 27, 57-64.

#	Paper	IF	Citations
348	Andropause: a quality-of-life issue in older males. **2006**, 90, 1005-23		38
347	Risks of androgen therapy. **2006**, 3, 404-409		1
346	Effect of testosterone on ex vivo vascular reactivity in man. **2006**, 111, 265-74		60
345	Androgen deficiency in aging men. **2006**, 5, 417-424		1
344	Coronary artery disease in men: the role of sex hormones. **2006**, 2, 247-50		
343	Prognosis and therapy approaches of cardiac cachexia. **2006**, 21, 229-33		53
342	Bibliography. Current world literature. Molecular genetics. **2006**, 21, 249-53		
341	Bibliography. Current world literature. Imaging and echocardiography. **2006**, 21, 529-35		
340	Novel aspects of endothelium-dependent regulation of vascular tone. **2006**, 70, 840-53		76
339	¿Se necesitan más fármacos para el tratamiento de la insuficiencia cardiaca? Diferencias entre los ensayos clínicos y la práctica clínica. **2006**, 6, 25C-28C		1
338	Study protocol to investigate the effects of testosterone therapy as an adjunct to exercise rehabilitation in hypogonadal males with chronic heart failure. **2006**, 6, 46		12
337	Heart failure therapy: testosterone replacement and its implications. *European Heart Journal*, **2006**, 27, 10-2	9.5	13
336	Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. **2006**, 147, 2675-80		90
335	Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. **2006**, 114, 1829-37		290
334	Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. **2007**, 30, 911-7		371
333	The effect of testosterone on insulin sensitivity in men with heart failure. **2007**, 9, 44-50		62
332	Testosterone replacement therapy. **2007**, 68, 547-53		4

331	Metabolic perturbation in chronic heart failure: time to redress the balance?. **2007**, 3, 131-5		
330	Effects of testosterone on cytokines and left ventricular remodeling following heart failure. **2007**, 20, 847-52		26
329	Bibliography. Current world literature. Molecular genetics. **2007**, 22, 225-45		
328	Testosterone Replacement Therapy: What We Know Is Not Yet Enough. **2007**, 82, 11-13		6
327	How does cachexia influence survival in cancer, heart failure and other chronic diseases?. **2007**, 1, 299-305		25
326	Why men's hearts break: cardiovascular effects of sex steroids. *Endocrinology and Metabolism Clinics of North America*, **2007**, 36, 365-77	5.5	42
325	Testosterone replacement therapy: what we know is not yet enough. **2007**, 82, 11-3		8
324	Hypogonadism in men with type 2 diabetes. **2007**, 24, 269-277		6
323	Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study. **2007**, 66, 235-45		45
322	Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. **2007**, 61, 611-21		28
321	Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?. **2007**, 61, 622-32		25
320	Handgrip strength predicts sexual behavior, body morphology, and aggression in male college students. **2007**, 28, 423-429		166
319	Myocardial protection in man--from research concept to clinical practice. **2007**, 12, 345-62		20
318	The triad of erectile dysfunction, hypogonadism and the metabolic syndrome. **2008**, 62, 791-8		72
317	Metabolic and cardiovascular effects of androgen deprivation therapy. **2008**, 102, 1509-14		51
316	Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. **2008**, 68, 59-65		21
315	Testosterone and cardiovascular disease. **2008**, 5, S18-S20		1
314	Clinical awareness and diagnosis of male hypogonadism. **2008**, 5, S26-S34		2

313	Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. **2009**, 30, 1-9		175
312	Testosterone improves cardiac dysfunction by suppressing the biosynthesis of tumor necrosis factor-□during heart failure. **2008**, 1, 200-202		
311	Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. **2008**, 159, 507-14		342
310	Testosterone in chronic heart failure. **2009**, 37, 183-196		35
309	The intrinsic resistance of female hearts to an ischemic insult is abrogated in primary cardiac hypertrophy. **2008**, 294, H1514-22		29
308	Palliative symptom management in patients with heart failure. **2008**, 16, 241-249		9
307	Role of putrescine on androgen-elicited positive inotropism in the left atrium of rats. **2008**, 52, 161-6		8
306	Inverse correlation between testosterone and ventricle ejection fraction, hemodynamics and exercise capacity in heart failure patients with erectile dysfunction. **2008**, 34, 302-10; discussion 310-2		24
305	Testosterone for the aging male; current evidence and recommended practice. **2008**, 3, 25-44		89
304	Androgen therapy and atherosclerotic cardiovascular disease. *Vascular Health and Risk Management*, **2008**, Volume 4, 11-21	4.4	7
303	Sexuality and ageing. **2009**, 238-252		9
302	Nutrition and heart failure: impact of drug therapies and management strategies. **2009**, 24, 60-75		30
301	Clinical problem-solving. When past is prologue. **2009**, 360, 1016-22		3
300	Heart failure as a multiple hormonal deficiency syndrome. *Circulation: Heart Failure*, **2009**, 2, 151-6	7.6	64
299	ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. **2009**, 12, 5-12		144
298	Therapeutic potential of testosterone gels. **2009**, 5, 227-245		
297	Overview of emerging pharmacotherapy in chronic heart failure. **2009**, 10, 2055-74		4
296	Perils of weight loss: the advantage of being obese in patients with heart failure. **2009**, 7, 263-7		3

295	Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. **2009**, 11, 28-38		36
294	Effect of testosterone replacement therapy on arterial stiffness in older hypogonadal men. **2009**, 160, 839-46		59
293	Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. **2009**, 161, 443-9		114
292	Testosterone replacement therapy. **2009**, 37, 445-449		5
291	Testosterone in men‚ health: a new role for an old hormone. **2009**, 6, 169-176		5
290	Influence of gender and sex hormones on 5alpha-dihydrotestosterone elicited effect in isolated left atria of rats: Role of beta-adrenoceptors and ornithine decarboxylase activity. **2009**, 604, 103-10		7
289	Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure. **2009**, 619, 68-74		12
288	Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. **2009**, 55, 121-30		195
287	Cachexia and aging: an update based on the Fourth International Cachexia Meeting. **2009**, 13, 47-55		44
286	Investigation, treatment and monitoring of late-onset hypogonadism in males. **2009**, 32, 1-10		101
285	Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. **2009**, 15, 442-50		69
284	Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. **2009**, 54, 919-27		331
283	Testosterone: a novel therapeutic approach in chronic heart failure?. **2009**, 54, 928-9		25
282	The dark side of testosterone deficiency: III. Cardiovascular disease. **2009**, 30, 477-94		184
281	ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. *International Journal of Impotence Research*, **2009**, 21, 1-8	2.3	114
280	Cardiovascular Endocrinology. **2009**,		2
279	The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. **2009**, 207, 318-27		115
278	Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. **2009**, 27, 187-93		30

277	STROKE. **2009**, 15, 81-90		
276	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. **2010**, 2010, 245-247		
275	Testosterone and coronary artery disease. *Cardiology in Review*, **2010**, 18, 251-7	3.2	14
274	Testosterone and heart failure. **2010**, 17, 262-8		33
273	Testosterone deficiency and exercise intolerance in heart failure: treatment implications. **2010**, 7, 59-65		23
272	Cardiovascular aspects of sexual medicine. **2010**, 7, 1608-26		80
271	Endocrine aspects of male sexual dysfunctions. **2010**, 7, 1627-56		142
270	Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. **2010**, 7, 3495-503		173
269	₱What should I do with a 60-year old man with a slightly low serum total testosterone concentration and normal levels of serum gonadotrophins₱. **2010**, 72, 584-8		4
268	Testosterone and male ageing: spinning the wheels. **2010**, 193, 379-80		5
267	Growth hormone and testosterone in heart failure therapy. **2010**, 11, 1835-44		6
266	The relationship between testosterone deficiency and frailty in elderly men. **2010**, 4, 529-38		3
265	Heart Failure in Clinical Practice. **2010**,		4
264	Testosterone levels and cardiovascular disease. **2010**, 96, 1787-8		11
263	Low circulating androgens and mortality risk in heart failure. **2010**, 96, 504-9		52
262	Adverse events associated with testosterone administration. **2010**, 363, 109-22		1065
261	Low serum testosterone and increased mortality in men with coronary heart disease. **2010**, 96, 1821-5		171
260	New insights into sexual dimorphism during progression of heart failure and rhythm disorders. **2010**, 151, 1837-45		14

259	Testosterone administration induces protection against global myocardial ischemia. **2010**, 42, 122-9		17
258	Anabolic steroids and frailty. **2010**, 11, 533-6		13
257	Inadequate masking of testosterone. **2010**, 55, 2290; author reply 2290-1		3
256	Reply. **2010**, 55, 2290-2291		1
255	Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. **2010**, 56, 1310-6		142
254	Possible interactive effect of testosterone and aldosterone receptor antagonists on cardiac apoptosis. **2010**, 63, 760-2		1
253	Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. **2010**, 33, 776-83		70
252	Cardiovascular disease and androgens: a review. **2010**, 142, 8-14		56
251	Testosterone deficiency: a risk factor for cardiovascular disease?. **2010**, 21, 496-503		124
250	Posible interacci□ entre testosterona y antagonistas de receptores de aldosterona en la apoptosis cardiaca. **2010**, 63, 760-762		1
249	DHEA, important source of sex steroids in men and even more in women. **2010**, 182, 97-148		116
248	Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. **2010**, 95, 2560-75		538
247	Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. **2011**, 13, 482-8		54
246	Update on the safety of testosterone therapy in cardiac disease. **2011**, 10, 697-704		6
245	Chronic heart failure: current evidence, challenges to therapy, and future directions. **2011**, 11, 153-71		36
244	Testosterone replacement therapy and cardiovascular risk factors modification. **2011**, 14, 83-90		17
243	Testosterone, cardiovascular disease and the metabolic syndrome. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2011**, 25, 337-53	6.5	115
242	Gender-based differences in cardiac diseases. **2011**, 25, 81-9		12

241	Alterations in Nutrition and Body Mass in Heart Failure. **2011**, 330-345	
240	Emerging Strategies in the Treatment of Heart Failure. **2011**, 728-741	
239	Sex hormones are associated with right ventricular structure and function: The MESA-right ventricle study. **2011**, 183, 659-67	116
238	Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. **2011**, 4, 1183-8	26
237	An old emperor finds new clothing: rejuvenation in our time. *Asian Journal of Andrology*, **2011**, 13, 125-9 2.8	17
236	Anabolic status and functional impairment in men with mild chronic heart failure. **2011**, 108, 862-6	12
235	Male hormonal contraception: potential risks and benefits. **2011**, 12, 107-17	13
234	Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia. **2011**, 2, 191-200	34
233	Frailty: diagnosis and management. **2011**, 15, 667-70	47
232	Androgen deficiency in heart failure. **2011**, 8, 131-9	7
231	Aromatase deficiency confers paradoxical postischemic cardioprotection. **2011**, 152, 4937-47	38
230	The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men's Health Study). **2011**, 14, 231-6	24
229	Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. **2011**, 34, 1669-75	234
228	Should frailty be treated with testosterone?. **2011**, 14, 1-3	15
227	Testosterone therapy: treatment of metabolic disturbances in heart failure. **2011**, 16, 14-23	16
226	Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies - a mini-review. **2011**, 57, 193-202	25
225	Myths and truths of growth hormone and testosterone therapy in heart failure. **2011**, 9, 711-20	9
224	Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. **2011**, 66, 1090-9	117

223	Are men at risk? The role of testosterone in cardiovascular morbidity. **2012**, 2, 275-7		1
222	Androgens and cardiovascular risk1). **2012**, 1-9		
221	Testosterone supplementation in heart failure: a meta-analysis. *Circulation: Heart Failure*, **2012**, 5, 315-21	7.6	138
220	Effects of androgens on cardiovascular remodeling. **2012**, 214, 1-10		25
219	Androgene und kardiovaskuläres Risiko/Androgens and cardiovascular risk. **2012**, 36,		
218	Testosterone deficiency in older men: a problem worth treating. **2012**, 27, 152-63		13
217	Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. **2012**, 105, 68-76		31
216	Molecular and cellular mechanisms of skeletal muscle atrophy: an update. **2012**, 3, 163-79		190
215	Preserved muscle protein metabolism in obese patients with chronic heart failure. **2012**, 160, 102-8		23
214	Hormonal effects on blood vessels. **2012**, 35, 363-9		17
213	Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. *Asian Journal of Andrology*, **2012**, 14, 604-11	2.8	24
212	Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study. **2012**, 164, 893-901		71
211	Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. **2012**, 6, 143-8		19
210	Testosterone and heart failure. *Endocrine*, **2012**, 42, 272-7	4	37
209	Testosterone and cardiovascular disease in men. *Asian Journal of Andrology*, **2012**, 14, 428-35	2.8	58
208	Drug-Induced Cardiomyopathies. **2012**,		
207	Testosterone and cardiovascular disease. 207-234		2
206	Effects of testosterone on norepinephrine release in isolated rat heart. **2012**, 32, 42-46		2

205	Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. **2012**, 9, 54-67	45
204	Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. **2013**, 11, 108	389
203	Testosterone therapy in women: myths and misconceptions. **2013**, 74, 230-4	27
202	The effect of severe androgen deficiency on physical function in male patients with cancer. **2013**, 45, 892-900	4
201	Cortisol and testosterone in hair as biological markers of systolic heart failure. **2013**, 38, 2875-82	35
200	Testosterone treatment and exercise capacity. **2013**, 166, e21	2
199	Male hypogonadism and testosterone replacement therapy. **2013**, 41, 557-561	4
198	Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. **2013**, 169, 725-33	259
197	Exercise and testosterone supplementation in male chronic heart failure patients with low testosterone status. **2013**, 166, e23	3
196	Hypogonadism, testosterone, and nursing home residents. **2013**, 14, 381-3	10
195	Treatment of Hypogonadism in Men. **2013**, 59-87	1
194	Frailty, sarcopenia, and hormones. *Endocrinology and Metabolism Clinics of North America*, **2013**, 42, 391-405	84
193	Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. **2013**, 9, 479-93	159
192	Clinical Urologic Endocrinology. **2013**,	
191	Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. **2013**, 68, 153-60	46
190	Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. **2013**, 2, e000272	131
189	Andropause: Current concepts. **2013**, 17, S621-9	24
188	Androgen modulates cardiac fibrosis contributing to gender differences on heart failure. **2013**, 16, 22-7	9

187	Testosterone: a vascular hormone in health and disease. **2013**, 217, R47-71		164
186	Exercise intolerance in chronic heart failure--skeletal muscle dysfunction and potential therapies. **2013**, 77, 293-300		77
185	Testosterone deficiency in male: a risk factor for heart failure. **2013**, 13, 92-9		20
184	A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. *Canadian Urological Association Journal*, **2010**, 4, 269-75	1.2	30
183	The use of hormonal therapy in "andropause": the pro side. *Canadian Urological Association Journal*, **2008**, 2, 43-6	1.2	4
182	Androgens and cardiac diseases. **2013**, 80, 161-9		0
181	The use of hormonal therapy in "andropause": the con side. *Canadian Urological Association Journal*, **2008**, 2, 47-8	1.2	2
180	Beneficial effects of testosterone therapy on functional capacity, cardiovascular parameters, and quality of life in patients with congestive heart failure. **2014**, 2014, 392432		31
179	Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. **2014**, 5, 287-96		51
178	Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. **2014**, 12, 211		89
177	Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. **2014**, 13, 1327-51		219
176	Evaluation of long-term pituitary functions in patients with severe ventricular arrhythmia: a pilot study. **2014**, 37, 1057-64		4
175	Activit˙physique, nutrition, et insuffisance cardiaque chronique. **2014**, 28, 327-335		1
174	Testosterone and mortality. **2014**, 81, 477-87		44
173	Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. *Asian Journal of Andrology*, **2014**, 16, 192-202	2.8	134
172	Impact of castration on changes in left ventricular diastolic pressure-volume relations induced by chronic adrenergic stimulation in rats. **2014**, 63, 562-6		2
171	The Association of Free Testosterone Levels in Men and Lifestyle Factors and Chronic Disease Status: A North Texas Healthy Heart Study. **2014**, 5, 173-9		4
170	The effect of testosterone on cardiovascular disease: a critical review of the literature. **2014**, 8, 470-91		10

169	Serum testosterone levels and mortality in men with CKD stages 3-4. **2014**, 64, 367-74	48
168	Male hypogonadism. **2014**, 383, 1250-63	164
167	Exercise intolerance in chronic heart failure: the role of cortisol and the catabolic state. **2014**, 11, 70-9	18
166	Controversies in Diagnosis and Treatment of Hypogonadism. **2014**, 6, 89-93	
165	Death by testosterone? We think not!. **2014**, 11, 624-9	39
164	The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer. **2014**, 12, 399-407	16
163	Metabolic impairment in heart failure: the myocardial and systemic perspective. **2014**, 64, 1388-400	147
162	Androgen attenuates cardiac fibroblasts activations through modulations of transforming growth factor-□and angiotensin II signaling. **2014**, 176, 386-93	33
161	Outcomes of testosterone therapy in men with testosterone deficiency (TD): part II. **2014**, 88, 117-26	22
160	Testosterone and obesity. **2015**, 16, 581-606	189
159	Aldosterone and testosterone: two steroid hormones structurally related but with opposite electrophysiological properties during myocardial ischemia-reperfusion. **2015**, 29, 341-51	10
158	Hormone replacement therapy in heart failure. **2015**, 30, 277-84	28
157	Testosterone replacement and cardiovascular disease risk. **2015**, 4, 100-107	0
156	Testosterone deficiency increases hospital readmission and mortality rates in male patients with heart failure. **2015**, 105, 256-64	15
155	Cardiovascular effects of hormone therapy for prostate cancer. **2015**, 7, 129-38	12
154	Testosterone suppresses ventricular remodeling and improves left ventricular function in rats following myocardial infarction. **2015**, 9, 1283-1291	14
153	Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management. **2015**, 22, 1084-95	7
152	Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk. **2015**, 9, 340-4	2

151	Testosterone therapy and cardiovascular risk: advances and controversies. **2015**, 90, 224-51		137
150	Reply to the letter "androgens in cardiac fibrosis and other cardiovascular mechanisms". **2015**, 182, 340-1		2
149	The role of testosterone therapy in cardiovascular mortality: culprit or innocent bystander?. **2015**, 17, 490		4
148	Testosterone in men with hypogonadism and high cardiovascular risk, Pros. *Endocrine*, **2015**, 50, 320-5	4	2
147	A novel application of salivary testosterone in systolic heart failure. **2015**, 4, 28-38		
146	The practical management of testosterone deficiency in men. **2015**, 12, 641-50		41
145	Androgens in cardiac fibrosis and other cardiovascular mechanisms. **2015**, 179, 190-2		12
144	Amino acids and derivatives, a new treatment of chronic heart failure?. **2015**, 20, 39-51		20
143	Dilated Cardiomyopathy after Sequential Therapy with Abiraterone and Enzalutamide. **2016**, 02,		
142	Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. **2016**, 8, E269-77		12
141	Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. **2016**, 118, 731-741		80
140	Progesterone therapy for the treatment of non-cancer cachexia: a systematic review. **2016**, 6, 276-86		8
139	Effect of Exercise Training and Testosterone Replacement on Skeletal Muscle Wasting in Patients With Heart Failure With Testosterone Deficiency. **2016**, 91, 575-86		42
138	Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes. **2016**, 84, 55-62		11
137	The search for efficient diagnostic and prognostic biomarkers of heart failure. **2016**, 12, 327-37		1
136	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. **2016**, 19, 221-230		9
135	Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. **2016**, 4, 943-956		68
134	Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?. **2016**, 18, 75		7

133	Screening for hypogonadism: real-world considerations. **2016**, 7, 27-32	1
132	Predictive value of serum testosterone for type 2 diabetes risk assessment in men. **2016**, 16, 26	16
131	Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. **2016**, 91, 881-96	69
130	Testosterone Attenuates Age-Related Fall in Aerobic Function in Mobility Limited Older Men With Low Testosterone. **2016**, 101, 2562-9	23
129	Testosterone and Cardiovascular Disease. **2016**, 67, 545-57	185
128	Androgen receptor (AR) in cardiovascular diseases. **2016**, 229, R1-R16	38
127	Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?. **2016**, 43, 247-60	5
126	Cardiac cachexia - Up-to-date 2015. **2016**, 58, e431-e438	6
125	Testosterone Replacement Therapy and Mortality in Older Men. **2016**, 39, 117-30	14
124	Roles of Testosterone Replacement in Cardiac Ischemia-Reperfusion Injury. **2016**, 21, 27-43	18
123	Pharmacologic Options for the Treatment of Sarcopenia. **2016**, 98, 319-33	115
122	Androgen Physiology, Pharmacology, and Abuse. **2016**, 2368-2393.e16	4
121	Androgen Deficiency Disorders. **2016**, 2394-2420.e13	3
120	Muscle wasting and cachexia in heart failure: mechanisms and therapies. **2017**, 14, 323-341	160
119	Prevention of β-adrenergic-induced Adverse Cardiac Remodeling by Gonadectomy in Male but Not Female Spontaneously Hypertensive Rats. **2017**, 70, 202-209	2
118	Testosterone replacement therapy and the risk of stroke in men: A systematic review. **2017**, 106, 31-37	10
117	Cardiovascular Health, Erectile Dysfunction, and Testosterone Replacement: Controversies and Correlations. **2017**, 110, 1-8	9
116	Early testosterone replacement attenuates intracellular calcium dyshomeostasis in the heart of testosterone-deprived male rats. **2017**, 67, 22-30	5

115	Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism). **2017**, 1043, 527-558		3
114	Sex Differences in Muscle Wasting. **2017**, 1043, 153-197		80
113	Androgen status in non-diabetic elderly men with heart failure. **2017**, 20, 215-224		8
112	Mechanistic Pathways of Sex Differences in Cardiovascular Disease. **2017**, 97, 1-37		290
111	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. **2017**, 130, 293-305		67
110	Role of Testosterone in the Treatment of Cardiovascular Disease. **2017**, 12, 83-87		7
109	Hormones and Sarcopenia. **2017**, 23, 4484-4492		35
108	Hormone treatments in congestive heart failure. **2018**, 46, 2063-2081		7
107	The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. **2018**, 89, 3-10		13
106	The Intersection of Medicine and Urology: An Emerging Paradigm of Sexual Function, Cardiometabolic Risk, Bone Health, and Men's Health Centers. **2018**, 102, 399-415		4
105	Screening for Hypogonadism in Primary Healthcare: How to do this Effectively. **2018**, 126, 176-181		
104	Testosterone and Cardiovascular Health. **2018**, 93, 83-100		49
103	Complex Association of Sex Hormones on Left Ventricular Systolic Function: Insight into Sexual Dimorphism. **2018**, 31, 231-240.e1		11
102	Muscular responses to testosterone replacement vary by administration route: a systematic review and meta-analysis. **2018**, 9, 465-481		35
101	Effect of testosterone supplementation on nitroso-redox imbalance, cardiac metabolism markers, and S100 proteins expression in the heart of castrated male rats. **2018**, 6, 74-85		3
100	Sex hormone levels and change in left ventricular structure among men and post-menopausal women: The Multi-Ethnic Study of Atherosclerosis (MESA). **2018**, 108, 37-44		34
99	Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system. *Asian Journal of Andrology*, **2018**, 20, 120-130	2.8	35
98	OBSOLETE: Hormonal Therapy for Heart Failure. **2018**,		

97	Testosterone treatment in chronic heart failure. Review of literature and future perspectives. **2018**, 88, 976	3
96	Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. **2018**, 15, 820-838	54
95	Testosterone, myocardial function, and mortality. **2018**, 23, 773-788	19
94	Hormonal Therapy in the Treatment of Chronic Heart Failure. **2018**, 508-516	0
93	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure: A Randomized Double-Blind Controlled Pilot Study. **2018**, 23, 543-550	11
92	Hormone Replacement Therapy in Men. **2018**, 735-740	
91	GONADOPENIA AND AGING IN MEN. **2018**, 24, 375-385	4
90	Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. **2019**, 7, 636-649	27
89	Testosterone and male rejuvenation. **2019**, 61, 128-137	3
88	Anti-androgenic therapy with finasteride in patients with chronic heart failure - a retrospective propensity score based analysis. **2019**, 9, 10139	2
87	New insights into the pathogenesis and treatment of sarcopenia in chronic heart failure. **2019**, 9, 4019-4029	38
86	Combined effects of growth hormone and testosterone replacement treatment in heart failure. **2019**, 6, 1216-1221	7
85	Efficacy of Nasal Testosterone Gel (Natesto) Stratified by Baseline Endogenous Testosterone Levels. **2019**, 3, 1652-1662	9
84	The effects of prenatal androgen exposure on cardiac function and tolerance to ischemia/reperfusion injury in male and female rats during adulthood. **2019**, 229, 251-260	5
83	Testosterone replacement therapy and cardiovascular risk. **2019**, 16, 555-574	69
82	Testosterone deficiency reduces cardiac hypertrophy in a rat model of severe volume overload. **2019**, 7, e14088	6
81	Testosterone Deficiency: A Review and Comparison of Current Guidelines. **2019**, 16, 812-820	17
80	Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency. **2019**, 321-354	

79	An update on heart disease risk associated with testosterone boosting medications. **2019**, 18, 321-332		11
78	The My-T study: Patient satisfaction and preference comparing topical and nasal testosterone therapies. *Canadian Urological Association Journal*, **2019**, 384-389	1.2	6
77	Hormonal Replacement Therapy in Heart Failure: Focus on Growth Hormone and Testosterone. **2019**, 15, 377-391		10
76	Pharmacological management of cardiac cachexia: a review of potential therapy options. **2019**, 24, 617-623		7
75	Paradoxical effect of testosterone supplementation therapy on cardiac ischemia/reperfusion injury in aged rats. **2019**, 191, 105335		5
74	Endogenous circulating testosterone and sex hormone-binding globulin levels and measures of myocardial structure and function: the Framingham Heart Study. **2019**, 7, 307-314		4
73	Metabolic Dysfunction in Continuous-Flow Left Ventricular Assist Devices Patients and Outcomes. **2019**, 8, e013278		2
72	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. **2019**, 10, 125-170		39
71	Tissue Resident CCR2- and CCR2+ Cardiac Macrophages Differentially Orchestrate Monocyte Recruitment and Fate Specification Following Myocardial Injury. **2019**, 124, 263-278		207
70	Chronic testosterone administration improves cardiac contractility and has a beneficial effect on the haemostatic system by enhancing fibrinolytic activity and inducing hypocoagulation in healthy rats. **2019**, 125, 311-320		1
69	Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. **2020**, 71, 23-31		17
68	Anabolic Deficiencies in Heart Failure: Ready for Prime Time?. **2020**, 16, 11-21		2
67	Suppression of myofilament cross-bridge kinetic in the heart of orchidectomized rats. **2020**, 261, 118342		1
66	Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system. **2020**, 50, 491-512		1
65	Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. **2020**, 172, 105-118		24
64	Late-onset hypogonadism: Reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. **2020**, 8, 1614-1627		7
63	Heart Failure-Induced Skeletal Muscle Wasting. **2020**, 17, 299-308		4
62	Hypogonadism management and cardiovascular health. **2020**, 132, 35-41		1

61	Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events. **2020**, 129, 110423		1
60	Testosterone replacement therapy. **2020**, 8, 1551-1566		25
59	Bone in heart failure. **2020**, 11, 381-393		5
58	Testosterone Supplementation in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. **2020**, 11, 110		10
57	Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. **2021**, 18, 83-98		4
56	Physiological testosterone attenuates profibrotic activities of rat cardiac fibroblasts through modulation of nitric oxide and calcium homeostasis. **2021**, 68, 307-315		2
55	Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure. **2021**, 22, 257-274		10
54	Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry. **2021**,		6
53	Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices. **2021**, 13,		
52	Diagnosis and Management of Testosterone Deficiency in men: A review of the European and American Urology Associations. **2021**, 75, 217-228		
51	Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men. **2021**, 2021, 5527973		3
50	Testosterone therapy and cardiovascular diseases. **2021**,		4
49	Adjuvant Testosterone Therapy in Chronic Heart Failure (ATTIC) – A Randomised Open-Label Trial.		
48	Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure. *Clinical Nutrition*, **2021**, 40, 5141-5155	5.9	2
47	Testosterone, cardiomyopathies, and heart failure: a narrative review. *Asian Journal of Andrology*, **2021**, 23, 348-356	2.8	8
46	Testicular Dysfunction in Systemic Diseases. **2010**, 339-364		6
45	Hypogonadismus und infertilität bei systemischen Erkrankungen. **2009**, 339-364		2
44	Androgen Physiology, Pharmacology, and Abuse. **2010**, 2469-2498		9

43	Testosterone level and mortality in elderly men with systolic chronic heart failure. *Asian Journal of Andrology*, **2011**, 13, 759-63	2.8	16
42	The Role of Testosterone in Patients With Heart Failure: A Systematic Review. *Cardiology in Review*, **2021**, 29, 156-161	3.2	2
41	Gonads are the heart of the matter. *Menopause*, **2007**, 14, 342-4	2.5	5
40	Sarcopenia in heart failure: mechanisms and therapeutic strategies. *Journal of Geriatric Cardiology*, **2016**, 13, 615-24	1.7	39
39	Treatment of Men for "Low Testosterone": A Systematic Review. *PLoS ONE*, **2016**, 11, e0162480	3.7	61
38	The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment.. *Obesity and Metabolism*, **2016**, 13, 15-31	0.6	1
37	Reposição hormonal e exercício físico no tratamento da insuficiência cardíaca: revisão sistemática. *Revista Brasileira De Medicina Do Esporte*, **2011**, 17, 431-434	0.5	1
36	A 3-year observation of testosterone deficiency in Chinese patients with chronic heart failure. *Oncotarget*, **2017**, 8, 79835-79842	3.3	4
35	Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. *Asian Journal of Andrology*, **2015**, 17, 187-91	2.8	22
34	Trials of testosterone replacement reporting cardiovascular adverse events. *Asian Journal of Andrology*, **2018**, 20, 131-137	2.8	4
33	Central and peripheral testosterone effects in men with heart failure: An approach for cardiovascular research. *World Journal of Cardiology*, **2015**, 7, 504-10	2.1	3
32	Hormonal Profile in Patients With Dilated Cardiomyopathy. *Research in Cardiovascular Medicine*, **2015**, 4, e27631	0.4	7
31	Disability and Frailty in Older Patients with Cardiovascular Disease. *Fundamental and Clinical Cardiology*, **2008**, 811-818		1
30	Cardiac Cachexia in Chronic Heart Failure: The Metabolic Facet of CHF. **2010**, 165-185		1
29	Rekomendatsii ISA, ISSAM, EAU, EAA i ASA: diagnostika, lechenie i monitorirovanie vozrastnogogipogonadizma u muzhchin. *Obesity and Metabolism*, **2010**, 7, 56-63	0.6	
28	Hormone Replacement Therapy with Testosterone. **2013**, 1-19		
27	Hormone Replacement Therapy with Testosterone and the Vascular System. **2015**, 4681-4693		
26	Androgen Therapy for Hypogonadism in Men with Chronic Illnesses. **2017**, 399-422		0

25	Hypogonadism in Systemic Diseases. *Endocrinology*, **2017**, 829-879	0.1	1
24	Hypogonadism in Systemic Diseases. *Endocrinology*, **2017**, 1-51	0.1	0
23	Correlation between Serum Testosterone Levels and Functional Capacity in Males with Congestive Heart Failure. *Research Journal of Cardiology*, **2017**, 10, 8-12		
22	Therapist-Assisted Progressive Resistance Training, Protein Supplements, and Testosterone Injections in Frail Older Men with Testosterone Deficiency: Protocol for a Randomized Placebo-Controlled Trial. *JMIR Research Protocols*, **2018**, 7, e71	2	
21	Benefits and risks of testosterone therapy in older men. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2019**, 71, 217-229	4.4	1
20	Endocrine system dysfunction and chronic heart failure: a clinical perspective. *Endocrine*, **2021**, 1	4	1
19	Hormonal Regulation of the Vascular System: An Overview. **2009**, 1-15		
18	Dr. MoralesPrebuttal. *Canadian Urological Association Journal*, **2008**, 2, 49-50	1.2	
17	Androgen therapy and atherosclerotic cardiovascular disease. *Vascular Health and Risk Management*, **2008**, 4, 11-21	4.4	9
16	Association between Androgenic Hormone Levels and Left Ventricular Ejection Fraction. *The Journal of Tehran Heart Center*, **2010**, 5, 141-5	0.3	1
15	Synergistic effect of estradiol and testosterone protects against IL-6-inducedcardiomyocyte apoptosismediated by TGF-1. *International Journal of Clinical and Experimental Pathology*, **2018**, 11, 10-26	1.4	0
14	Therapeutic effects of androgens for cachexia. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2021**, 101598	6.5	1
13	Role of circulating molecules in age-related cardiovascular and metabolic disorders.. *Inflammation and Regeneration*, **2022**, 42, 2	10.9	0
12	Fertility Preservation in Hypogonadal Men. **2022**, 497-515		
11	Testosterone replacement therapy in hypogonadal male patients with hypogonadism and heart failure: a meta-analysis of randomized controlled studies. *Minerva Urology and Nephrology*, **2021**,	2.3	0
10	Testosterone replacement therapy and cardiovascular disease.. *International Journal of Impotence Research*, **2022**,	2.3	0
9	Testosterone Treatment As a Function-Promoting Therapy in Sarcopenia Associated with Aging and Chronic Disease.. *Endocrinology and Metabolism Clinics of North America*, **2022**, 51, 187-204	5.5	1
8	Testosterone and cardiovascular disease - a literature review. *Scripta Scientifica Medica*, **2022**, 54, 9	0.1	

7	Anabolic Deficiencies in Heart Failure: Ready for Prime Time?. *Cardiology Clinics*, **2022**, 40, 149-159	2.5	0
6	Testosterone, Hypogonadism, and Heart Failure.. *Circulation: Heart Failure*, **2022**, 101161CIRCHEARTFAILURE12100875	7.6	2
5	Adjuvant testosterone therapy in chronic heart failure (ATTIC): a randomised open-label trial. *BMJ Open*, **2022**, 12, e056994	3	1
4	The relationship between serum sex hormone and cardiac echocardiographic findings in healthy men. **2022**, 12,		
3	Androgens and Non-Genomic vascular responses in hypertension. **2022**, 203, 115200		0
2	Testosterontherapie.		0
1	The role of androgens in pressure overload myocardial hypertrophy. 14,		0